INB-200 shows significantly improved progression-free survival in glioblastoma patients, with favorable safety profile and no serious toxicities reported. Repeated doses of INB-200 demonstrated an ...
Ivonescimab plus chemotherapy improved PFS by 40% compared to Tevimbra in advanced squamous NSCLC, with a median PFS of 11.14 months versus 6.9 months. The study demonstrated consistent PFS benefits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results